This study focuses on using asciminib, a new medicine, for people who have just found out they have Chronic Myeloid Leukemia in its early stage (CML-CP). Asciminib is taken as a pill every day, and doctors will check the patient's response using a special blood test called PCR (polymerase chain reaction). If needed, after up to 3 years, some may add other medications like dasatinib, imatinib, or nilotinib. The goal is to see how well asciminib works and if it's safe for patients.

• Study Length: Up to 8 years, with treatment lasting about 5 years.
• Visits: Regular visits for blood tests and health checks.
• Risks: Possible side effects from the medication; serious conditions may require stopping the study.

To join, you must be 18 or older, newly diagnosed with CML-CP, and meet specific health criteria. If you're pregnant, have other serious illnesses, or previously took asciminib, you may not be eligible. The study is set to enroll 50 participants across multiple locations, aiming to improve treatment outcomes for CML-CP patients.